Comparative Pharmacology
Head-to-head clinical analysis: E E S 400 versus ILOTYCIN GLUCEPTATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E E S 400 versus ILOTYCIN GLUCEPTATE.
E.E.S. 400 vs ILOTYCIN GLUCEPTATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin, a macrolide antibiotic, binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis. At high concentrations, it may also inhibit RNA synthesis.
Erythromycin gluceptate is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide chain elongation.
Erythromycin ethylsuccinate 400 mg orally every 6 hours. For severe infections, up to 4 g/day in divided doses.
Erythromycin gluceptate (Ilotycin Gluceptate) is administered intravenously at a dose of 250-500 mg every 6 hours for adults. Maximum daily dose: 4 g.
None Documented
None Documented
1.5-2.0 hours in adults with normal renal function; may be prolonged in hepatic impairment (up to 5-6 hours) but not significantly changed in renal disease.
Terminal elimination half-life is approximately 1.5-2 hours in adults with normal renal function; may be prolonged in hepatic impairment (up to 5-6 hours).
Primarily hepatic (biliary) excretion of unchanged drug and metabolites; approximately 2-5% renal excretion of unchanged drug; 5-15% fecal elimination.
Primarily hepatic metabolism and biliary excretion; about 10-15% excreted unchanged in urine; some fecal elimination due to biliary excretion.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic